Abstract
The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Current Drug Therapy
Title:Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Volume: 8 Issue: 3
Author(s): Verma Nitika and Khatri Kapil
Affiliation:
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Abstract: The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Export Options
About this article
Cite this article as:
Nitika Verma and Kapil Khatri, Microtubule Targeting Agents: A Benchmark in Cancer Therapy, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113086660011
DOI https://dx.doi.org/10.2174/15748855113086660011 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Cancer Risk and Nullity of Glutathione-S-Transferase Mu and Theta 1 in Occupational Pesticide Workers
Current Pharmaceutical Biotechnology Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 2
Current Women`s Health Reviews Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine
Current Signal Transduction Therapy Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Preparation and Characterization of Stattic-Loaded Albumin Nanoparticles for Antimetastatic Cancer Treatment
Drug Delivery Letters TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Proteomics as a Tool in the Pharmaceutical Drug Design Process
Current Pharmaceutical Design Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry Current Management of In Situ and Invasive Cervical Adenocarcinoma
Current Women`s Health Reviews Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety